This new research category award recognises Cell Signaling Technology as the company doing best in the global cancer biology market.
From the data generated through CiteAb we are able to gain a really clear picture of the way antibodies are used around the world. We can tell which countries are investing most in research using antibodies, which companies are seeing growth or decline, which antibodies are most successful and which areas of research are seeing growth.
Dr Andrew Chalmers, Founder of CiteAb, said: “The winner for this award was established based on CiteAb data for the most citations achieved in the cancer biology market between January 2017 and December 2017. Cell Signaling Technology should be proud to be supporting more cancer researchers than any other supplier.”
Explore additional categories featuring in the 2018 CiteAb Awards.
Highlighting an outstanding individual who has made a significant impact in the reagent sector.
Shedding light on the reagent supplier that researchers have been most impressed by in 2017.
Recognising the most exciting new antibody validation initiative in the sector from 2017.
Celebrating reagents or instruments that are set to change the sector.
Rewarding the company with the most antibody citations during 2017.
An exciting award for the company with the largest percentage increase in citations during 2017.
A new category recognising the chemical probes supplier with the most citations during 2017.
A new category, recognising the chemical probes company with the largest percentage increase in citations in 2017.
Awarding the company that has secured the most custom antibody citations over the past 3 years.
An award to recognise the company with the most citations achieved in the cancer biology market during 2017.
This award recognises the antibody company which has achieved the largest increase in antibody market share over the past five years.
Recognising the most cited flow cytometer instrument during 2017.